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Abstract
Background: Introduction of antiretroviral therapy (ART) in sub-Saharan Africa was a hot debate due to many
concerns about adherence, logistics and resistance. Currently, it has been significantly scaled up. However as the
WHO clinico-immunological approaches for initiation and monitoring of ART in the region lacks viral load
determination and drug resistance monitoring, HIV infected adults and children may be at risk for “unrecognized”
virologic failure and the subsequent development of antiretroviral drug resistance. This study evaluates the
virological efficacy and immunological recovery of HIV/AIDS patients under ART.
Methods: Consecutive HIV-1 infected adults (N = 100) and children (N = 100) who have been receiving ART for up
to 6 years at Gondar University Hospital, Ethiopia were enrolled following the WHO protocol for assessment of
acquired drug resistance. Magnitude of viral suppression, genotypic drug resistance mutations and patterns of
CD4+ T cell recovery were determined using standard virological and immunological methods.
Results: Virological suppression (HIV RNA < 40 copies/ml) was observed in 82 and 87% of adults and children on a
median time of 24 months on ART, respectively. Mutation K103N conferring resistance to non nucleoside reverse
transcriptase inhibitors and thymidine analogue mutations (M41L, L210W) were found only in one adult and child
patient, respectively. Median CD4+ T cell count has increased from baseline 124 to 266 (IQR: 203–306) and 345 (IQR:
17–1435) to 998 (IQR: 678–2205) cells/mm3 in adults and children respectively after 12 months of ART. Nevertheless,
small but significant number of clinically asymptomatic adults (16%) and children (13%) had low level viraemia
(HIV-1 RNA 41–1000 copies/ml).
Conclusions: Majority of both adults (82%) and children (87%) who received ART showed high viral suppression
and immunological recovery. This indicates that despite limited resources in the setting virological efficacy can be
sustained for a substantial length of time and also enhance immunological recovery irrespective of age. However,
the presence of drug resistance mutations and low level viraemia among clinically asymptomatic patients
highlights the need for virological monitoring.
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Background
The provision of antiretroviral therapy (ART) has re-
duced mortality of people living with HIV-infection
[1,2]. Conceivably, the use of ART especially in low in-
come countries with sub optimal medication and
patient’s follow-up may favour the emergence and
transmission of drug resistant HIV-1 mutations. Particu-
larly long term use of ART can lead to drug resistance
especially among those individuals with previous mono-
or dual-therapy or when temporary discontinuation in
therapy has occurred [3]. This poses the risk that HIV
with definite resistance profiles may be transmitted to
uninfected people and thus will impair the success of
ART programs. Moreover, introducing ART particularly
to sub-Saharan Africa was debated controversially be-
cause of concerns about adherence and subsequent
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development of drug resistance, poor infrastructure, lo-
gistic and human capacity, and cost-effectiveness [4].
However, the World Health Organization (WHO) pilot
ART feasibility study catalysed global efforts and ART
has been significantly scaled up [5]. Nevertheless, long
term challenges of providing ART will become increas-
ingly evident, including late drug toxicities, treatment
failure and emergence of drug resistance [3,6]. Good
levels of adherence to ART in the first year of treatment
[7,8] and a short-term virological efficacy comparable to
industrialized countries [9] have been documented from
some African countries. But, it has been shown that 10%
of patients who commence ART develop some form of
genotypic drug resistance after two years, and almost
30% of patients develop viral failure within six years after
starting ART [10], thereby representing a threat to the
control of transmitted multi drug resistance [11]. Studies
from sub-Saharan Africa countries revealed a level of
drug resistance as high as 50% [12-15]. Moreover, Afri-
can patients with very low CD4+ T cell counts have a
high risk of mortality both before and during the initial
months of ART [16,17] and advanced pre-treatment im-
munodeficiency is also reported to be associated with re-
duced capacity for restoration of CD4+ T cell counts and
its functional responses during ART [18-20]. This raises
the concern that many patients entering ART pro-
grammes in sub-Saharan Africa may have limited poten-
tial for immune recovery. Despite the rapid scaling up of
ART and its positive outcomes in adults, as of 2012 only
30% of HIV infected children (≤14 years) eligible for
ART were receiving it. Moreover, the limited access of
paediatric regimens, the challenges of paediatric ART ad-
herence and the likelihood of HIV drug resistance devel-
opment raise great public health concern about drug
resistance in children receiving ART [21].
In Ethiopia HIV prevalence is estimated to be 1.5%
among the general population with an estimate of about
800, 000 people living with HIV (78% adults and 22%
children <14 years). By the end of 2012, there were
249,174 adults and 16,000 children on treatment, of
whom 135 children and 865 adults were receiving sec-
ond line drugs. However, in some regions 40% of pa-
tients who were enrolled to ART dropped out from
treatment. The over all current ART coverage for adult
populations is high (86% of estimated eligible). Con-
versely, the coverage of ART for children is low (only
20% of estimated eligible) (http://www.etharc.org/). Ac-
cess to optimal laboratory monitoring with viral load
testing is not available. Hence, ART initiation and moni-
toring is based on the WHO clinico-immunological ap-
proach. However, as this approach lacks viral load
determination and drug resistance monitoring by sequen-
cing of reverse transcriptase gene segments HIV infected
adults and children may be at risk for “unrecognized”
virologic failure and the subsequent development of anti-
retroviral drug resistance. The aim of this study was to
evaluate the virological efficacy and CD4+ T cell recovery
among HIV/AIDS adults and children patients who were
on ART for up to 6 years.
Methods
Patients and ART
Patients were assessed at Gondar University hospital
(GUH), Northwest Ethiopia. GUH is a referral and
teaching hospital responsible for the treatment of more
than 8, 000 HIV infected adults and 400 children. Adult
patients with WHO clinical stage 4 irrespective of CD4+
T cell count, stage 3 with CD4+ T cell count ≤ 350 cells/
mm3, or patients with CD4+ T cell count ≤ 200 cell/
mm3 in any clinical stages are eligible for ART [22].
HIV-infected children with WHO clinical stage III or IV
disease (regardless of CD4 cell count) or children with
CD4 percentage < 20% (for children < 18 months) or
<15% (for children >18 months), regardless of clinical
stage, were eligible to initiate ART [21]. However, the
adult’s treatment protocol is revised since 2010 accord-
ing to WHO recommendation for resource limiting set-
tings towards initiation of ART at CD4+ T count of 350
cells/mm3 [23]. Similarly, all infants <12 months with
WHO clinical stage III or IV disease (regardless of CD4
cell count) or children with CD4 percentage <20% (for
children <36 months) or <15% (for children aged > 36
months), regardless of clinical stage, were eligible to ini-
tiate ART [22]. ART in Ethiopia consists of generic low-
cost fixed-dose combination (FDC) of two NRTI and
one NNRTI with first line regimens of lamivudine (3TC)
combined with stavudine (d4T) or zidovudine (AZT),
and either nevirapine (NVP) or efavirenz (EFV) (Table 1).
For anaemic patients d4T substitutes AZT and for tuber-
culosis patients treated with rifampicin NVP replaces
EFV. Co-trimoxazole prophylaxis was given to all pa-
tients included in this study. ART and care was free of
charge and there were no interruptions in drug supply.
In the event of first-line treatment failure, second-line
regimens with addition of lopinavir/retrovir were started
[21,22]. Other antiretroviral drugs such as protease, inte-
grase and entry inhibitors as well as co-receptor antago-
nists are not in use. Both diagnosis of first-line
treatment failure and criteria for switching to second-
line drugs is based on clinical findings and CD4+ T cell
count as viral load is not routinely measured.
Study design and selection procedure
This longitudinal study follows the WHO protocol for
assessment of acquired drug resistance for adults [24].
Consecutive HIV-infected adult (N = 100) and children
(N = 100) who had received first-line ART for more than
12 months and visiting Gondar Hospital from June to
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November 2008 were included in the study. Patients
who had interrupted treatment or patients transferred
from another ART clinic or pregnant women or those
with known chronic illness were excluded.
Clinical and laboratory assessment
Minimal socio-demographic data and relevant clinical
features of the patients were retrieved from medical re-
cords. About 10 ml venous blood was collected in a tube
containing ethylene diamine tetra-acetic acid (EDTA).
After centrifugation (956 rcf for 5 minutes) plasma was
separated and stored at −40°C until further used. CD4+
T cell count was done at baseline and at 6 months inter-
val using the FACSCount flow cytometer (Becton
Dickinson, San Jose, CA, USA) following the manufac-
turer’s protocol. The laboratory is accredited by the
American Society of Clinical Pathologists and partici-
pated in external quality control and assurance program.
RNA extraction and plasma viral load determination
RNA was extracted from 0.6 ml of plasma with the
Abbott m2000sp automated sample preparation system
(Abbott Molecular, Des Plaines, IL, USA) according to
manufacturer’s instructions. Plasma viral load was mea-
sured using Quantitative RealTime HIV-1 assay by the
Abbott m2000rt instrument with a lower detection limit
of 40 copies/ml.
Sequence determination of HIV-1 pol gene
Viral RNA was reverse transcribed using AMV reverse
transcriptase (Promega Corporation, WI, USA) and the
outer primer HIVrt (5′TGTTTTACATCATTAGTGTG
3′). The entire protease (PR) and partial (76%) reverse
transcriptase (RT) regions of the pol gene were amplified
using an in house assay. In brief, Phusion Hot Start High-
Fidelity DNA polymerase (Finnzymes, Espoo, Finland)
was used in nested PCR with the outer primers HIVpcr-
For1 (5′TGATGACAGCATGTCAGGGAGTGG3′) and
HIVpcrRev1 (5′GGCTCTTGATAAATTTGATATGTC-
CATTG3′) yielding a 1757 bp amplicon, and subsequently
by the inner primers HIVpcrFor2 (5′AGCCAACAGCCC-
CACCAG3′) and HIVpcrRev2 (5′CTGTATTTCTGC-
TATTAAGTCTTTTG 3′) yielding a 1389 bp amplicon.
Initial denaturation was done at 98°C for 2 minutes
followed by 40 cycles consisting of 10 seconds of denatur-
ation at 98°C and 25 seconds of annealing at 64°C for the
first round outer primers (HIVpcrFor1 and HIVpcrRev1)
PCR and at 53°C for the nested inner primers (HIVpcr-
For2 and HIVpcrRev2) PCR with a 40 seconds extension
at 72°C for both and final extension for 5 min at 72°C.
Purified PCR products were subjected to direct sequen-
cing of both the sense and antisense strands using Big Dye
Terminator Cycle Sequencing Ready Reaction kit (Applied
Biosystems, Foster City, CA, USA). For each sample, six
separate sequencing reactions were done using the two
inner PCR primers and four additional internal primers:
HIVseq1 (5′GTTAAACAATGGCCATTGACAGA3′), HIV-
seq2 (5′TGGAAAGGATCACCAGCAATATT3′), HIVseq3
(5′GGGCCATCCATTCCTGGCT3′) and HIVseq4 (5′
2CCATCCCTGTGGAAGCACATT3′) which allowed a
double coverage of the pol region. All primers positions
are matched to HIV-1HXB2 (GenBank accession number
K03455). Both forward and reverse overlapping sequences
were manually edited with the Geneious Basic software
version 5.4 [25]. Genotypic drug resistance was defined ac-
cording to The Stanford University HIV Drug-Resistance
Database (http://hivdb.stanford.edu/).
Table 1 Baseline characteristics of adult HIV/AIDS










Non anaemic 38 33













1a: 3TC + d4T + NVP 39 57
1b: 3TC + d4T + EFV 32 5
1c: 3TC + AZT** + NVP 17 35
1d: 3TC + AZT + EFV*** 12 3
Keys: 3TC (Lamivudine), d4T (Stavidine), NVP (Nevirapine), EFV (Efavirenz), AZT
(Zidovidine); The difference in ART regimen between adults and children is due to
the high rates of Tuberculosis in adults; **AZT replaced by d4T in anaemic
patients; *** EFV replaced by NVP in patients with TB when on rifampicin; aAge
and gender specific classification of anaemia according to WHO (http://www.
who.int/vmnis/indicators/haemoglobin); bAge specific classification for
ART eligibility.
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Statistical analysis
The main outcomes of interest were virological suppression
(HIV RNA < 40 copies/ml), drug resistance mutation/s and
immunological recovery. Virological suppression was de-
fined as HIV viral load <40 copies/ml. Immunological re-
covery was evaluated based on CD4+ T cell response:
patients who failed to achieve an absolute increase in CD4+
T cell count from baseline by at least 50 cell/mm3 at 12
months were defined as immunological non responders.
Those patients who achieved an absolute CD4+ T cell count
of 200 cells/mm3 at the 12 months visit were defined as im-
munological responders. Absolute response in CD4+ T cell
count was calculated at every 6 months intervals and cate-
gorized into 2 phases: Phase I from base line to 12 months,
Phase II from 13–48 months. Duration of ART was
rounded to the nearest half or full year. Univariate analysis
was performed for sex, age, WHO clinical stages, ART regi-
men at baseline, duration of ART, haematocrit value and
CD4+ T cell count. Logistic regression was used to study
associations between baseline characteristics and out-
comes. A p-value of less than 0.05 was considered sta-
tistically significant. The statistical analyses were
carried out using SPSS statistical software version 17.
Ethical issues
The work meets relevant ethical guidelines. Institutional
ethical clearance was obtained from the University of
Gondar Ethics Review Committee. Written and/or ver-
bal informed consent was also obtained from study sub-
jects and/or families and/or guardians.
Results
Baseline patient’s characteristics
A total of 200 HIV-infected patients (100 adults and 100
children) were included in the present study with the
mean ± standard deviation age of 34.2 ± 8.4 and 5.3 ±
1.2 years, respectively. At baseline the median CD4+ T
cell count for adults and children was 144 cells/mm3
(Inter quartile range (IQR) 91.25-181.75) and 345 (IQR
17–1435). The median duration with ART was 24
months (IQR: 18.00-29.25) for both adults and children.
The proportions of patients with CD4+ T cell strata,
WHO clinical stages, the duration of time on ART, the
main therapeutic regimen are summarized in Table 1. A
standard first-line ART regimen as defined by national
ART guidelines was initiated: 3TC + d4T + NVP for 39%
of adults and children; 3TC + AZT + NVP for 12 and
57% of adults and children (Table 1). All the children ex-
cept two were born from HIV infected mothers without
exposure to single dose nevirapine (sdNVP) and com-
bined ART for prevention of mother to child transmis-
sion (PMTCT) prophylaxis.
Virological response to ART
Virological suppression was observed in 82% of the
adults in median time of 24 months on ART. The pro-
portion of the adult patients with plasma HIV RNA level
of 41–400 copies/ml, 401–1000 copies/ml and >10,000
copies/ml were 14, 2 and 2, respectively. There was no
significant difference in the proportion of patients with
baseline CD4+ T cell counts of 50–99 cells/ml (OR 2.8;
95% CI 0.143-55.56), 100–199 cell/mm3 (OR 3.6; 95% CI
0.35-32.32) or with baseline CD4+ T cell counts of >200
cells/mm3 (OR 3.23; 95% CI 0.38-27.34) who achieved a
viral load of <40 copies/ ml as compared with those with
a baseline CD4+ T count of < 50 cells/mm3. Samples
with plasma viral load of >400 copies/ml were amplified
and genotyping was successful in 4 patients and all were
found to be HIV-1 subtype C. Mutation K103N confer-
ring resistance to the NNRTIs NVP, delavirdine (DLV),
EFV and etravirine (ETR) was found in one patient.
Polymorphic accessory mutation to the protease inhibi-
tor class of ARVs at codon 74 (T74S) was observed in 2
patients. In 3 patients, naturally occurring polymor-
phisms that may or may not have an impact on levels of
drug resistance were found (mutations M36I, H69K and
L89M) (Table 2). After additional 24 months of ART, pa-
tients were retrieved. Although the attrition rate was
high, 22 patients were found still on ART and all of them
were virological suppressed.
Similar to the adults, high virological suppression rate
(87%) was observed in children in a median time of 24
months on ART. One HIV-1 subtype C isolate with thy-
midine analogue mutations (M41L, L210W) was de-
tected. Low level viraemia (HIV-1 RNA in the range of
41–1000 copies/ml) was observed in a single sample of
13 clinically asymptomatic children.
CD4+ T cell response to ART
The proportion of adult HIV infected patients with CD4+
T cell counts <100 cells/mm3 was 31% at baseline. This
proportion had decreased to 6% by month 12 of the treat-
ment. The median CD4+ T cell count increased nearly
two-fold from baseline, reaching 266 cells/mm3 after 12
months on ART (Figure 1). It further increased reaching
336, 397 and 422 cells/mm3 after 24, 36 and 48 months of
ART, respectively. The rate of CD4+ T cell count increase
in the first 12 months period was higher than the rates in
both the 13–24 months and 25–48 months intervals (P <
0.001, 95% CI, 63.27-88.01). Thus, the pattern of CD4+ T
cell count increase on average in 6 months time, and in the
next 7–12 months was 75.64 cells/mm3 and 58.8 cell/mm3,
respectively, with statistically significant mean difference (P
= 0.023). However, the further increase in the ensuing 12
months of ART was slower with a mean of 47.33 cells/mm3
at 13–18 months and 3 cells/mm3 at 19–24 months and
did not reach at statistical significance level. Accordingly,
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the rate of CD4+ T cell count increase was divided into
2 phases: a rapid phase (0–12 months; mean = 11.5
cells/mm3/month), and a slower phase (13–48 months;
mean = 3 cells/mm3/month) (Figure 1).
In a similar trend, the median absolute CD4+ T cell
count of children has increased from 345 (IQR 17
to1435) to 998 (IQR 678–2205) in a median time of 12
months on ART. The CD4+ T cell counts after a median
time of 24 months on ART were similar between vir-
aemic (n = 13) and aviraemic (n = 87) children (median
(IQR) 996 (730–1524) versus 946 (472–1102) (P = 0.10)
cell/mm3.
Effect of baseline CD4+ T cell count and ART regimens on
rates of CD4+ T cell increase
Adult patients with low baseline CD4+ T cell count
(i.e. < 50 cells/mm3) at the initiation of ART required
more time to recover compared to those patients with a
higher baseline CD4+ T cell count (Figure 2). In the 48
months period, none of the patients reached a final CD4+
T cell count of 500 cells/mm3. Patients with lowest CD4+
T cell count strata (<50 cells/mm3) did not reach the
lower threshold of 350 cells/mm3 up to 42 months on
ART, though there was a remarkable increase to an aver-
age of 276 cells/mm3 (Figure 2). However, patients with
average baseline CD4+ T cell count strata 50–99, 100–199
and 200–349 attained 350 cells/mm3 by 33, 28, and 14
months after ART, respectively. Among those who had a
CD4+ T cell count measurement at 12 months (n = 96),
the CD4+ T cell count increased by >50 cells/mm3 in 16
(16.7%) patients. Of these, the viral load was suppressed
below LLD- lower limit of detection (<40 copies/ml) in 13
patients in a median time of 24 months on ART. Among
patients with baseline CD4+ T cell counts of <50, 50–99,
Table 2 Genotyping drug resistance mutations in patients with ART failurea
Code ART regimenb Time on ART PVLc Mutations Subtype
(months) PR RT
0053 1a/1c 40 13945 M36I, H69K, T74S, L89M - C
1959 1c 26 598 M36I, H69K, T74S, L89M - C
3438 1d 13 495 M36I, H69K, L89M - C
1739 1b 25 18239 M36I, H69K, L89M K103N C
2369 1c 19 25678 M36I, H69K, L89M M41L, L210W C
aART failure was defined as plasma viral load of > 400 copies/ml; b: As indicated in Table 1; cPVL: Plasma viral load in copies/ml.
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Time on ART (Months)
Figure 1 CD4+T cell count over a period of 48 months. Trend in CD4+ T cell recovery among HIV/AIDS adult patients over a period of 48
months on ART. The straight line in the graph is the trend line showing the increase of CD4+ T cells at a steady rate over 48 months on ART. The
R-squared value is 0.9125 shows a good fit of the line to the data. The equation (Y = 31.35X + 153.65) on the graph is the regression analysis that
extends a trend line in a chart beyond the actual data to predict future values.
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100–199 and ≥ 200 cells/mm3, the proportions of patients
who were immunological non-responders were 1, 1, 10
and 4, (16%, 4%, 20%, 30%) respectively. Failure to attain
200 cells/mm3 was not significantly associated (Table 3)
with older age, or lower baseline CD4+ T cell count (P >
0.05 in all comparisons). The recovery of CD4+ T cell
count follows similar pattern independent of the antiretro-
viral drug regimen up to 24 months in both adults and
children. However, patients with ART regimen 1c and 1d
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Figure 2 Mean CD4+ T cell recovery in different strata during ART. The mean CD4+ T cell recovery of adult patients with low baseline CD4+
T cell strata (< 50 cells/mm3) and higher CD4+ T (200–349 cells/mm3) at the initiation of ART over a period of 48 months on ART.
Table 3 Logistic regression models predicting overall change in CD4+ T cell count of adults during ART
Variables aRisk of non-response bRisk of failure to attain >200 CD4 cell
OR (95% CI) P value OR (95% CI) P value
Sex Female 0.2 (0.65-0.658) 0.08 6.5
Male 0.4 (0.16-1.33) 0.150
Age (years) <29 0.76 0.52
30-39 1.68 (0.401-7.09) 0.47 14.0 (1.62-122.7) 0.160
≥40 1.17 (0.32-4.21) 0.81 1.88 (0.60-5.90) 0.278
WHO Clinical Stage I I 0.69 0.4
II 0.154 (0.007-3.57) 0.244 0.038 (0.002-0.894) 0.045
III 0.346 (0.027-4.418 0.414 0.769 (0.043-13.866) 0.8
IV 0.359 (0.043-3.013) 0.345 0.325 (0.039-2.7) 0.32
Haematocrit value < 37% 3.0 3.0
≥ 37% 2.54 (0.848-7.514) 0.096 2.16 (0.751-6.253) 0.153
ART regimen
3TC + d4T + NVP 1.66 (0.349-7.9) 0.542 4.857 (0.974-24.227) 0.054
3TC + d4T + EFV 1.87 (0.36-9.64) 0.450 2.286 (0.50-10.44) 0.286
3TC + AZT + NVP 6.00 (0.53-67.27) 0.146 2.667 (0.463-15.35) 0.272
3TC + AZT + EFV 0.54 0.288
CD4+ T cell count <50 0.313 0.99
50-99 2.00 (0.174-22.94) 0.578 0.578 0.99 (0.00-) 0.9
100-199 9.20 (0.91-93.02) 0.060 0.060 0.99 (0.00-) 0.9
200-349 1.68 (0.436-6.47) 0.451 0.451 0.99 (0.00-) 0.9
aRisk of immunological non-response (an increase of <50 cells/mm3 at 12 months).
bFailure to attain an absolute CD4+ cell count of ≥ 200 cells/mm3 after 48 weeks ART).
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and 42 months of ART. During the study period, there
was a treatment switching in 15 patients due to peripheral
neuropathy secondary to d4T associated toxicity (n = 7),
AZT induced anaemia (n = 2) and d4T related lipoathro-
phy (n = 1). The incidence of tuberculosis during the first
6 months on ART was 7% and hence NVP was substituted
by EFV in those patients.
Discussion
The 82% suppression rates and the low level of HIV
drug resistance in adults with a median time of 24
months on first line ART in the present study from
Ethiopia demonstrates a high level of effectiveness of the
antiretroviral agents in the setting. The result is in agree-
ment with data from Europe and North America [9] and
with a more recent report from Tanzania [26] where
88% viral suppression (defined as viral load below 400
copies/ml) with a median follow up time of 23 months
has been described. A good short term virological effi-
cacy rates have been reported and a systematic review
on virological outcomes after 12 months ART from low-
to-middle-income countries where 83-86% of virological
efficacy on treatment was reported [27]. The high viro-
logical suppression rate of 87% with low-level drug re-
sistance among the paediatric age groups of this study is
somewhat unexpected too but is similar to a recent
study from Mozambique [28]. On the other hand, the
detection of low level viraemia (13%) and thymidine
analogue mutation (1%) in children documented to re-
ceive PMTCT prophylaxis is expected. The viral sup-
pression rates in both adult and children for up to four
years after starting first line ART in a setting where
nearly half of the population living under poverty line
are affected by various co-morbid infectious diseases and
where access to ART is largely restricted to two drug
classes is encouraging. The results exceeded the WHO
suggested target of ≥70% [24] and are similar to reports
from other settings [19,20,26-28].
The high rate of virological suppression may have an
impact on HIV prevention and reducing the overall risk
of transmission at a population level. It has been sug-
gested that scaling up of ART results in a level of viro-
logical suppression at the population level that will
reduce HIV transmission [29-32]. To reach this goal
ART should be extended to WHO groups I and II. How-
ever, the transient viraemia observed in this study among
both adults and children of clinically asymptomatic con-
ditions could be an early warning indicator for early
virological failure as some may suppress and others may
develop virological failure if tested in future. It does not
appear to affect CD4+ or CD8+ T-cell counts or the risk
of subsequent virological failure. Natural variation, assay
effects and adherence might all have a role.
The sustained virological efficacy on 6 years ART in
the present study might be attributed to free provision
of ART and care for HIV infected patients as it has been
previously shown to improve treatment efficacy [9] and
the pre and post ART provision readiness and adherence
counselling [8]. Moreover, it might have been related to
the strong collaboration between the nurses and the
community based workers that ensured a follow up of
patients and their network at village and home level. In
addition, because traditional medicine is culturally
entrenched, accessible, and affordable, up to 80% of the
Ethiopian population relies on traditional remedies
(herbs) as a primary source of health care [33]. This is
also the case for treatment of AIDS, but its contribution
to treatment success has not been evaluated and cer-
tainly not been demonstrated yet. Nevertheless, it is
claimed that certain medicinal plant remedies improve
the quality of life of patients with AIDS by reducing the
viral load [34].
It has been documented in European patients that,
after the initiation of ART, peripheral CD4+ T cell count
starts rising and continues so for at least 3–5 years [35].
Our data indicate a rapid initial increase in CD4+ T cell
count in the first 6 months and in the following 7–
12 months by 12.2 cells/mm3/month and 9.6 cell/mm3/
month, respectively, followed by almost linear rise in the
subsequent two years. This is in agreement with a report
that shows the rapid initial increase in CD4+ T cell count
in the first 6 months [36] which relies on a reduction in
T-cell activation and primarily consists of a release of
memory CD4+ T cells trapped in the lymphoid tissue.
However, the relative slow increase rate of CD4+ T cell
after 12 months of ART (13–24 months: mean = 6.3
cells/mm3/month; 25–48 months: mean = 3 cells/mm3/
month) and the gradual annual changes in CD4+ T cell
count thereafter suggests that the number of CD4+ T cell
may reach a plateau level sometime in the future. In this
case the naïve CD4+ T-lymphocytes from the thymus, as
well as memory CD4+ T-lymphocytes, contribute to the
reconstitution of the immune system [37]. The data also
shows that those patients with baseline CD4+ T cell
count of <50 cells/mm3 had similar rate of increase in
the first 6 months and the consecutive months com-
pared with higher baseline CD4+ T cell count. In most
HIV-1 infected individuals treated with ART, CD4+ T
cell recover to levels above 500 cells/mm3, at which
HIV-1 related clinical complications are rare [36]. None
of the patients in this study reached this threshold in 48
months of ART which could be associated with the nat-
urally lower CD4+ T cell counts in adult Ethiopians irre-
spective of HIV infection [38,39] and lower immune
recovery of Africans [40]. The relative high CD4+ T cell
counts and optimal CD4+ T cell recovery among chil-
dren in the current study is parallel with the data that
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shows the predominance of naive CD4+ T cell phenotype
at birth which is comparable to Caucasians [41].
Conclusions
After a median time of 24 months on ART, high viral
suppression rates in adults (82%) and children (87%)
were observed in Gondar hospital, Northwest Ethiopia
where patients usually present late in the course of in-
fection. This suggests that antiretroviral drugs in the set-
ting can sustain virological efficacy for a substantial
length of time and enhance immunological recovery ir-
respective of age. However, the presence of drug resist-
ance mutations and low level viraemia among clinically
asymptomatic patients highlights the need for regular
virological monitoring in order to optimise treatment
success and preserve future treatment options.
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